Insiders were net buyers of LumiraDx Limited's (NASDAQ:LMDX ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important ...
LumiraDx Limited (LMDX) has been on a downward spiral lately with significant selling pressure. After declining 25.5% over the past four weeks, the stock looks well positioned for a trend reversal as ...
LumiraDx Limited (LMDX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.16 per share a year ago. These figures are ...
As of May 11, 2023, the average one-year price target for LumiraDx is 1.87. The forecasts range from a low of 0.86 to a high of $3.99. The average price target represents an increase of 258.96% from ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
U.K.-based diagnostics company LumiraDx (NASDAQ:LMDX) lost ~20% premarket Tuesday after announcing an agreement to sell its point-of-care diagnostics platform and certain other assets to Roche ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results